OncoMatch/Clinical Trials/NCT07638852
Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
Is NCT07638852 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Radiotherapy followed by systemic therapy and Systemic therapy followed by radiotherapy for tnbc, triple negative breast cancer.
Treatment: Radiotherapy followed by systemic therapy · Systemic therapy followed by radiotherapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression (absence)
HR-negative is defined as ER-negative and PR-negative, with positive tumor cells accounting for <10% of all tumor cells
Required: PR (PGR) expression (absence)
HR-negative is defined as ER-negative and PR-negative, with positive tumor cells accounting for <10% of all tumor cells
Required: HER2 (ERBB2) wild-type
HER2-negative
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: platinum-based chemotherapy (cisplatin, carboplatin)
Exception: must have previously used only one regimen and meet platinum sensitivity: no progression during at least 4 cycles of platinum-based therapy, and subsequent disease progression occurring more than 3 months after the last platinum-based therapy
Must not have previously used platinum-based drugs, or must have previously used platinum-based drugs (cisplatin or carboplatin and only one regimen) and meet the following definition of platinum sensitivity: no progression during at least 4 cycles of platinum-based therapy, and subsequent disease progression occurring more than 3 months after the last platinum-based therapy
Cannot have received: bevacizumab (bevacizumab)
Exception: no disease progression during bevacizumab use and continued use would benefit the subject; short-term bevacizumab use to relieve cerebral edema
Previous use of bevacizumab...excluding the following: no disease progression during bevacizumab...use, investigators believe no drug resistance has been confirmed, and continued use would benefit the subject; short-term bevacizumab use to relieve cerebral edema
Cannot have received: anti-PD-1/PD-L1 therapy
Exception: no disease progression during PD-1/PD-L1 inhibitor use and continued use would benefit the subject
Previous use of...PD-1/PD-L1 inhibitors, excluding the following: no disease progression during...PD-1/PD-L1 inhibitor use, investigators believe no drug resistance has been confirmed, and continued use would benefit the subject
Lab requirements
Blood counts
ANC ≥1.5×10⁹/L; PLT ≥75×10⁹/L; Hb ≥90 g/L (blood transfusion or drug treatment is allowed to ensure hemoglobin levels)
Kidney function
Cr ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
Liver function
TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN (liver metastases ≤ 5.0 × ULN)
Cardiac function
LVEF ≥ 50%; 12-lead ECG: QTcF < 470 ms for women and < 450 ms for men
Organ function levels must meet the following requirements: ... see full text for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07638852 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior platinum-based chemotherapy, bevacizumab, anti-PD-1/PD-L1 therapy disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify